An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Idelalisib (Primary) ; Antineoplastics; Immunotherapies
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 25 Jun 2018 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 03 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.